https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT03213665&r=1
Tazemetostat in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin...
Tazemetostat in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with EZH2, SMARCB1, or...
https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma
FDA granted accelerated approval to tazemetostat for follicular lymphoma | FDA
Hematology / Oncology News Burst
accelerated approvalfdagrantedtazemetostatfollicular